Before a research peptide reaches a scientist's bench or a compounding pharmacy's formulation room, it usually passes through a layer of the supply chain that end-users never see. That layer is the contract development and manufacturing organization, or CDMO. These companies actually synthesize peptide active pharmaceutical ingredients (APIs) at scale, under quality systems that pharmaceutical clients, regulators, and contract researchers can audit.
What a peptide CDMO does
A CDMO is a B2B service provider. It handles some or all of the steps between a peptide's amino-acid sequence and a finished, tested bulk material. The core service is solid-phase peptide synthesis (SPPS), a well-established chemical process in which amino acids are assembled one residue at a time on a resin support. Most CDMOs offer more than synthesis:
- Purification (typically reverse-phase HPLC) to remove truncated sequences, deletion impurities, and synthesis by-products
- Analytical release testing: purity by HPLC, identity by mass spectrometry, residual solvent and counterion quantification
- Lyophilization (freeze-drying) to produce a stable powder for shipment
- Regulatory documentation: certificates of analysis (COAs), drug master files (DMFs), and ICH-compliant impurity profiles for clients seeking regulatory submissions
One distinction matters. A CDMO sells bulk API or intermediates to other businesses. It does not sell retail vials to individuals.
Where CDMOs sit in the supply chain
| Tier | Who they are | What they sell |
|---|---|---|
| CDMO / API manufacturer | Bachem, PolyPeptide Group, CordenPharma, others | Bulk synthesized peptide (grams–kilograms) |
| Finished-dose manufacturer | Pharma companies, compounding pharmacies | Formulated drug product |
| Research supplier | Peptide vendors selling online | Research-grade vials, for lab use |
| End user | Researchers, laboratories | Analytical or in-vitro research |
Bachem (Switzerland/USA) and the PolyPeptide Group are among the publicly named large-scale peptide CDMOs. Both publish capacity and capability information on their corporate sites. Smaller regional CDMOs serve biotech startups, academic institutions, and compounding pharmacies, often at lower minimum-order quantities.
Research-grade peptide suppliers occupy a separate tier. These are the vendors reviewed on platforms such as Finnrick, VialAudit, and PeptideBenchmark. They may source bulk material from CDMOs or from intermediate wholesalers, then repackage and resell it for research purposes. These products are sold for research use only and are not approved for human consumption unless they have been formulated and released as an approved drug through the appropriate regulatory pathway.
Quality systems and why they matter
Pharmaceutical-tier CDMOs operate under current Good Manufacturing Practice (cGMP) regulations, enforced by agencies such as the FDA (21 CFR Parts 210/211) and the EMA. cGMP requires validated processes, calibrated equipment, trained personnel, and thorough batch records. Those records support traceability when a quality problem surfaces downstream.
Standards bodies have moved to formalize what "quality" means for synthetic peptides specifically. The U.S. Pharmacopeia has published General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances," and proposed a companion chapter on starting materials for chemical peptide synthesis. Both are part of a broader effort to standardize identity, purity, and impurity expectations for this class of API.
Not every peptide on the research market comes from a cGMP facility. Research-grade suppliers vary considerably in how much analytical documentation they publish. Independent third-party testing services, such as Janoshik, exist partly because COA quality is inconsistent across the research supply chain. When reviewers on aggregator platforms call a vendor's peptide "third-party verified," they usually mean purity and identity testing done outside the vendor's own lab.
Why the CDMO tier is in the news
Demand for GLP-1 receptor agonists (the drug class behind semaglutide and tirzepatide products) has put unprecedented pressure on global peptide-manufacturing capacity. The largest CDMOs have responded with major investments:
- CordenPharma announced a roughly EUR 1 billion, three-year peptide program in July 2024, including a new GLP-1-capable plant in Muttenz, Switzerland. That site runs roughly EUR 500 million, has SPPS reactors larger than 5,000 L, and is expected to open around 2028, per BioProcess International.
- PolyPeptide Group reported in January 2025 a EUR 100 million expansion to double SPPS capacity at its Malmö, Sweden site, according to industry trade press.
- Bachem has publicly described multi-site capacity upgrades and a large multi-year supply commitment tied to rising peptide demand.
These expansions target approved, finished pharmaceutical products, not the research-vial market. But they shape the upstream bulk-API supply that some research suppliers ultimately draw on.
How this relates to research peptides
For anyone reading about specific research peptides on this site, whether GLP-1 analogues, growth-hormone-releasing peptides, or other compounds, the CDMO tier helps put quality claims in context. A vendor that can name its manufacturing source, publish a full analytical COA, and point to third-party corroboration offers more traceability than one that cannot. Traceability does not guarantee purity. Its absence, though, tells you something.
The FDA and EMA have both published guidance on peptide API manufacturing standards. The links below point to relevant public resources.